Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
PHASE4CompletedINTERVENTIONAL
Enrollment
10
Participants
Timeline
Start Date
August 31, 2005
Primary Completion Date
August 31, 2005
Study Completion Date
August 31, 2005
Conditions
Spondylitis, Ankylosing
Interventions
BIOLOGICAL
Remicade
Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT00778869 - Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED) | Biotech Hunter | Biotech Hunter